Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Yosef LA"'
Autor:
Candida Vitale, Valentina Griggio, Maria Todaro, Chiara Riganti, Rebecca Jones, Elia Boccellato, Francesca Perutelli, Francesca Arruga, Tiziana Vaisitti, Dimitar G. Efremov, Silvia Deaglio, Yosef Landesman, Benedetto Bruno, Marta Coscia
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Despite recent relevant therapeutic progresses, chronic lymphocytic leukemia (CLL) remains an incurable disease. Selinexor, an oral inhibitor of the nuclear export protein XPO1, is active as single agent in different hematologic malignancies
Externí odkaz:
https://doaj.org/article/9c2f6dcf66b5460ab64440b2e4a9be40
Autor:
Sonam Mittal, Ishaque Pulikkal Kadamberi, Hua Chang, Feng Wang, Sudhir Kumar, Shirng-Wern Tsaih, Christopher J. Walker, Pradeep Chaluvally-Raghavan, John Charlson, Yosef Landesman, Sunila Pradeep
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-6 (2023)
Abstract Leiomyosarcoma (LMS) is a rare soft tissue sarcoma (STS) that begins in smooth muscle tissue and most often initiates in the abdomen or uterus. Compared with other uterine cancers, uterine LMS (ULMS) is an aggressive tumor with poor prognosi
Externí odkaz:
https://doaj.org/article/91fda5397a8d4c568f9244b8871df4be
Autor:
Md. Hafiz Uddin, Mohammad Najeeb Al‐Hallak, Husain Yar Khan, Amro Aboukameel, Yiwei Li, Sahar F. Bannoura, Gregory Dyson, Seongho Kim, Yosef Mzannar, Ibrahim Azar, Tanya Odisho, Amr Mohamed, Yosef Landesman, Steve Kim, Rafic Beydoun, Ramzi M. Mohammad, Philip A. Philip, Anthony F. Shields, Asfar S. Azmi
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 12, Pp n/a-n/a (2023)
Abstract Background The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin‐bound (nab)‐paclitaxel (GemPac) necessitating the need for a more eff
Externí odkaz:
https://doaj.org/article/746a7f24c49c48c5878e393d3f6d9f55
Autor:
Yosef Laviv, Eilat Sapirstein, Andrew A Kanner, Shani Berkowitz, Suzana Fichman, Alexandra Benouaich-Amiel, Shlomit Yust-Katz, Ekkehard E Kasper, Tali Siegal
Publikováno v:
Clinical Pathology, Vol 16 (2023)
Background: Some glioblastoma multiforme (GBM) are characterized by the presence of gemistocytes (GCs), a unique phenotype of reactive astrocytes. Certain GCs can be identified as neoplastic cells but these cells were also found to be associated with
Externí odkaz:
https://doaj.org/article/e51e9e72442048b2a038c4e044cc50e4
Publikováno v:
Cancer Medicine, Vol 11, Iss 6, Pp 1484-1489 (2022)
Externí odkaz:
https://doaj.org/article/a4286f2850124536af485def523ba2f8
Autor:
Christopher J. Walker, Hua Chang, Leah Henegar, Trinayan Kashyap, Sharon Shacham, Josh Sommer, Michael J. Wick, Joan Levy, Yosef Landesman
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Chordoma is a rare cancer that grows in the base of the skull and along the mobile spine from remnants of embryonic notochord tissue. The cornerstone of current treatments is surgical excision with adjuvant radiation therapy, although complete surgic
Externí odkaz:
https://doaj.org/article/2439b9474a294b25943651078e71961a
Autor:
Eline Boons, Tatiane C. Nogueira, Tim Dierckx, Soraya Maria Menezes, Maarten Jacquemyn, Sharon Tamir, Yosef Landesman, Lourdes Farré, Achiléa Bittencourt, Keisuke Kataoka, Seishi Ogawa, Robert Snoeck, Graciela Andrei, Johan Van Weyenbergh, Dirk Daelemans
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-5 (2021)
Externí odkaz:
https://doaj.org/article/649a07bebf2b446c9c218bca5122f2e6
Autor:
Matan Ben-Zion Berliner, Lior Haim Katz, Estela Derazne, Hagai Levine, Lital Keinan-Boker, Alexandra Benouaich-Amiel, Omer Gal, Andrew A Kanner, Yosef Laviv, Asaf Honig, Tali Siegal, Jacob Mandel, Gilad Twig, Shlomit Yust-Katz
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Meningiomas are the most common primary central nervous system tumors. Potential risk factors include obesity, height, history of allergy/atopy, and autoimmune diseases, but findings are conflicting. This study sought to assess th
Externí odkaz:
https://doaj.org/article/1fac344ad2a34d3e9552c8e28a3efefc
Autor:
Jingshan Ho, Valerie Heong, Wei Peng Yong, Ross Soo, Cheng Ean Chee, Andrea Wong, Raghav Sundar, Yee Liang Thian, Anil Gopinathan, Mei Yan Pang, Priscillia Koe, Santhiay Nathan Jeraj, Phyu Pyar Soe, Mu Yar Soe, Tiffany Tang, Matthew C.H. Ng, David W.M. Tai, Tira J.Y. Tan, Hongmei Xu, Hua Chang, Yosef Landesman, Jatin Shah, Sharon Shacham, Soo Chin Lee, Daniel S.W. Tan, Boon Cher Goh, David S.P. Tan
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Purpose: This phase 1 study aims to evaluate the tolerability and the recommended phase 2 dose of selinexor in Asian patients with advanced or metastatic malignancies. Experimental Design: A total of 105 patients with advanced malignancies were enrol
Externí odkaz:
https://doaj.org/article/c79a3aab5cd24242a6a55312f1cb0bbf
Autor:
Frances Chow, Michael Berens, Sharon Tamir, Yosef Landesman, Christopher Walker, Mark Krailo, Steven Gore, Jana Portnow
Publikováno v:
Journal of Clinical and Translational Science, Vol 7, Pp 126-126 (2023)
OBJECTIVES/GOALS: Selinexor is a novel XPO1 inhibitor that blocks nuclear export, thus impairing DNA repair and causing apoptosis. Our goal was to conduct preclinical and clinical studies to test our hypothesis that selinexor’s efficacy is boosted
Externí odkaz:
https://doaj.org/article/3b387fb5faa140c6aeea72dc7a79b29e